Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026.

Pharming Group N.V. today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on Thursday May 28, 2026, at 14:00 CET.

Pharming Group N.V. today announced that its management will participate in the following investor conferences in the month of April:

Pharming Group N.V. today announced the filing of its Annual Report for the year ended December 31, 2025.

Pharming Group N.V. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older.

Pharming Group N.V. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026.

Pharming Group N.V. today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25-26, 2026.

Pharming Group N.V. today announced 2026 financial guidance and will highlight its advancing clinical-stage rare disease pipeline, including two major value-creating programs, at a virtual Investor Day taking place later today.